A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer.

Trial Profile

A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Irosustat (Primary) ; Megestrol
  • Indications Endometrial cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 26 Nov 2012 Planned end date changed from 1 Nov 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 29 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 06 Jun 2011 A futility analysis has shown that the primary endpoint 'Progression-free-survival' will not be met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top